Key result
A pharmacoinvasive strategy with recombinant prourokinase for STEMI showed comparable 5-year cardiovascular mortality to primary PCI.
Why the study?
The study was conducted to evaluate the long-term results of STEMI management using recombinant prourokinase compared to primary percutaneous coronary intervention.
Does a pharmacoinvasive strategy with recombinant prourokinase improve long-term outcomes compared to primary PCI in patients with STEMI?
Cohort (n=1,157)
Does a pharmacoinvasive strategy with recombinant prourokinase improve long-term outcomes compared to primary PCI in patients with STEMI?
Answers are grounded in this paper and cite their sources.
A pharmacoinvasive strategy using recombinant prourokinase yields comparable 5-year clinical outcomes to primary PCI in patients with STEMI.
Objective. To study the long-term results of ST-segment elevation myocardial infarction management using recombinant prourokinase or primary percutaneous coronary intervention (pPCI). Material and methods. Recombinant prourokinase and pPCI were used in 601 and 556 patients, respectively. We distinguished 2 groups of patients receiving comparable pharmacotherapy in accordance with current clinical guidelines. To assess the 5-year course of coronary artery disease after acute myocardial infarction (MI), we considered compliance with treatment regimens, repeated hospitalizations, incidence of angina pectoris, recurrent MI, progression of chronic heart failure (CHF) and mortality after 1, 3 and 5 years. Results. The number of patients complying with recommended treatment decreased over time in both groups (p=0.376). Readmissions after pharmacoinvasive strategy and PCI were observed in 38.8% and 31.3% of cases, respectively (p=0.368). Angina pectoris occurred in 28.1% and 29.9% of cases (p=0.51), recurrent MI — in 18.5% and 18.2% of cases (p=0.893), progression of CHF — in 13.0% and 13.8% of cases, respectively (p=0.664). Cardiovascular mortality after 1 year was 2.6% and 3.6%, after 3 years — 7.3% and 7.5%, after 5 years — 8.3% in both groups (p=0.775). Conclusion. Long-term course of coronary artery disease after STEMI management using pharmacoinvasive strategy with recombinant prourokinase and pPCI is comparable and does not have significant differences.
No takes yet. Share an insight, caveat, or question.
Milenkina et al. (2023) conducted a cohort in ST-segment elevation myocardial infarction (n=1,157). Recombinant prourokinase vs. Primary percutaneous coronary intervention (pPCI) was evaluated on Cardiovascular mortality after 5 years (p=0.775). A pharmacoinvasive strategy with recombinant prourokinase for STEMI showed comparable 5-year cardiovascular mortality to primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: